Clinical Trial: A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07163481) titled 'A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors' on Aug. 21.

Brief Summary: SoGreat is an open-label, single-arm, modular, two-stage, Phase Ib/II study. SoGreat (Part 1) is an open-label, modular, Phase Ib study.

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: HR-positive HER2-negative Metastatic Breast Cancer

Intervention: DRUG: Sacituzumab Govitecan + Fulvestrant

Sacituzumab Govitecan 10 mg/kg intravenously on Days 1 and 8 of 21-day cycles Combined with Fulvestrant 500 mg i...